-
Mashup Score: 3Regulatory Fate of Cancer Indications in the EU After Accelerated Approval in the US - 1 month(s) ago
This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Summer in the Hamptons Means $30 Berries and $120 Lobster Salad - 1 month(s) ago
The exclusive summertime playground also offers an $8.50 kimchi-cheddar croissant.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet-
Yeah! And significant part of the reason why berries cost $30 in the Hamptons is that Hamptonians shoulder most of the agricultural R&D cost. https://t.co/8vg4UkrYoM https://t.co/EdzVgCHigX
-
-
Mashup Score: 0The Last Smallpox Epidemic in Boston and the Vaccination Controversy, 1901–1903 | NEJM - 1 month(s) ago
One hundred years ago, Boston had its last epidemic of smallpox. We describe this final epidemic, the controversy over compulsory vaccination, and ethical issues that remain relevant today. Epidemi…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Everything old is new: great read! The Last Smallpox Epidemic in Boston and the Vaccination Controversy, 1901–1903 | New England Journal of Medicine https://t.co/55dWMHXxy7
-
-
Mashup Score: 0ClinicalTrials.gov - 1 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
Hematologist tells me ASC4FIRST could not have been run without imatinib because 2nd gen TKI too expensive. Generic dasatinib was available before ASC4FIRST even started. 🤦 https://t.co/c3NtDVtGL4
-
-
Mashup Score: 0Impact of computed tomography (CT) on lung cancer screening - 1 month(s) ago
Lung cancer is the most common cause of cancer-related death worldwide. Lung cancer survival is significantly dependent on when a person is diagnosed with the disease. It is essential to detect the disease as early as possible by radiography (chest x-ray) or by computed tomography (CT) scan, which is a more detai led type of radiography where multiple images of the lung are taken. The aim of this review was to gather information on the use of CT scan to detect lung cancer earlier and to find out if early
Source: www.cochrane.orgCategories: General Medicine News, Hem/OncsTweet-
@DrewMoghanaki @YaleMed @dramycummings @AshleyEProsper For people without a primary care doc, wouldn’t getting one, and all the care they provide be of greater priority than getting lung cancer screening? I’m confident that primary care can do better for people than LDCT. https://t.co/X2Hl4ms6IT
-
-
Mashup Score: 1Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours - 2 month(s) ago
Scientific Reports – Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
@OncBrothers @DrMMurphy @OncoAlert @CancerNetwrk @RenoHemonc @gyncsm @BijoyTelivala @drteplinsky @dr_yakupergun @RiosDoriaMD @womenofteal @ShannonWestin @Innov_Medicine @scserendipity1 NTRK? Prevalence: less than 0.18% in one study and all others found none https://t.co/KtNYxEPcYS BRAF? Probably only in low grade. Evidence informed testing!
-
-
Mashup Score: 2Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers | Journal of Clinical Oncology - 2 month(s) ago
PURPOSESecond primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease …Pathogenic BRCA1 and BRCA2 variant carriers are at higher second cancer risks after breast cancer.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
I guess this is updated info in the current era. Would have been way cooler to know how conditional risk of ca changes post dx in Brca carriers 2nd Primary ca Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers vs normal population https://t.co/Tc44sDQmyz
-
-
Mashup Score: 1Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers - 2 month(s) ago
npj Breast Cancer – Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers | npj Breast Cancer https://t.co/fzXmViIHd2
-
-
Mashup Score: 3Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers | Journal of Clinical Oncology - 2 month(s) ago
PURPOSESecond primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease …Pathogenic BRCA1 and BRCA2 variant carriers are at higher second cancer risks after breast cancer.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
I guess this is updated info in the current era. Would have been way cooler to know how conditional risk of ca changes post dx in Brca carriers 2nd Primary ca Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers vs normal population https://t.co/Tc44sDQmyz
-
-
Mashup Score: 0
We found a statistically significant difference between BICR and local IA of PFS in trials of IO in cancer. These results suggest that the double assessment is recommended in RCTs testing IO, especially in open-label trials.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet-
🥱 This is why we have ICR. This is why blinding is important. This is why we use dummy drugs ect. This is what we learned in the 80s. Good to see it re-validated. https://t.co/EpGY7QZkGi
-
RT @BMJOncology: Many European cancer drug approvals lack proven benefit for survival or quality of life. https://t.co/S9HKXB9qFq https:/…